Efficacy of solubilized vemurafenib administered via nasogastric tube

Farhad Khimani1, Christina Hoban, Vicky Williams

  • 1Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA.

Insights

Vemurafenib offers a targeted therapy for metastatic melanoma with BRAF mutations. This study presents an alternative administration method for patients unable to take oral medications.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Metastatic melanoma treatment was limited, with high-dose IL-2 having significant toxicities.
  • Activating BRAF mutations are present in 50-60% of melanoma patients, representing a key therapeutic target.

Observation:

  • Vemurafenib, a BRAF inhibitor, was approved by the US FDA in 2011 for melanoma treatment.
  • The standard administration of vemurafenib is oral.

Findings:

  • This work details an alternative method for administering vemurafenib.
  • This method is designed for patients who cannot take oral medications.

Implications:

  • Provides a crucial alternative administration route for vemurafenib, expanding treatment accessibility.
  • May improve treatment adherence and outcomes for select metastatic melanoma patients.

Related Concept Videos

Enteral Nutrition I: Orogastric and Nasogastric Feeding01:26

Enteral Nutrition I: Orogastric and Nasogastric Feeding

Enteral nutrition delivers nutrients directly to the stomach or small intestine through a tube. This method is appropriate for patients who cannot eat but still have a functioning digestive system. It is also beneficial for individuals with swallowing difficulties, anorexia, malabsorption, or those who have undergone gastrointestinal (GI) surgery.
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
3.1K